The New Pyrazolyltetrazole Derivative MSN20 Is Effective via Oral Delivery against Cutaneous Leishmaniasis

dc.creatorFaiões, Viviane dos Santos
dc.creatorSantos, Maurício Silva dos
dc.creatorBernardino, Alice Maria Rolim
dc.creatorCunha Júnior, Edézio Ferreira
dc.creatorCavalheiro, Marilene Marcuzzo do Canto
dc.creatorSantos, Eduardo Caio TorresF
dc.date2015-06-24T12:26:34Z
dc.date2015-06-24T12:26:34Z
dc.date2014
dc.date.accessioned2023-09-26T22:40:55Z
dc.date.available2023-09-26T22:40:55Z
dc.identifierFAIÕES, Viviane dos Santos et al. The New Pyrazolyltetrazole Derivative MSN20 Is Effective via Oral Delivery against Cutaneous Leishmaniasis. Antimicrob Agents Chemother, v.58, n.10, p.6290–6293, oct. 2014.
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/10953
dc.identifier10.1128/AAC.02874-14
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8881868
dc.descriptionAn orally delivered, safe and effective treatment for leishmaniasis is an unmet medical need. Azoles and the pyrazolylpyrimidine allopurinol present leishmanicidal activity, but their clinical efficacies are variable. Here, we describe the activity of the new pyrazolyltetrazole hybrid, 5-[5-amino-1-(4′-methoxyphenyl)1H-pyrazole-4-yl]1H-tetrazole (MSN20). MSN20 showed a 50% inhibitory concentration (IC50) of 22.3 μM against amastigotes of Leishmania amazonensis and reduced significantly the parasite load in infected mice, suggesting its utility as a lead compound for the development of an oral treatment for leishmaniasis.
dc.formatapplication/pdf
dc.languageeng
dc.publisherAmerican Society for Microbiology
dc.rightsopen access
dc.subjectLeishmaniose
dc.subjectTratamento
dc.subjectMedicamentos
dc.subjectLeishmaniasis
dc.subjectCutaneous Leishmaniasis
dc.subjectLeishmania amazonensis
dc.titleThe New Pyrazolyltetrazole Derivative MSN20 Is Effective via Oral Delivery against Cutaneous Leishmaniasis
dc.typeArticle


Este ítem pertenece a la siguiente institución